Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous umbilical cord blood mononuclear cells + pulmonary surfactant
- Development stage
- Unknown
- Lead developer
- yangjie
- Modality
- Cell Therapies
- Administration
- Intratracheal
01
Overview
Autologous umbilical cord blood mononuclear cells + pulmonary surfactant is an investigational combination cell therapy being developed for the prevention and treatment of bronchopulmonary dysplasia (BPD) in preterm infants. The therapy involves the intratracheal administration of the patient's own umbilical cord blood mononuclear cells (CBMNC) in conjunction with pulmonary surfactant (PS). CBMNCs are believed to exert therapeutic effects through the secretion of paracrine factors that reduce inflammation and promote lung tissue repair, while the pulmonary surfactant provides immediate structural stability to the alveoli, reducing the risk of collapse and further injury in ventilated neonates. This approach is currently being evaluated in Phase 1 clinical trials (e.g., NCT03855202) led by investigator Yang Jie.
- Other names
- CBMNC-yangjie-bronchopulmonary dysplasiaCBMNC + PSautologous umbilical cord blood mononuclear cells and pulmonary surfactant
Beyond the preview
Go deeper on autologous umbilical cord blood mononuclear cells + pulmonary surfactant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous umbilical cord blood mononuclear cells + pulmonary surfactant.